An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis.

IF 3.4 3区医学 Q3 IMMUNOLOGY

Clinical and experimental immunology Pub Date : 2024-10-16 DOI:10.1093/cei/uxae068

Han Zhou, Wei Liang, Hongtu Hu, Zikang Liu, Fan Chu, Guohua Ding

引用次数: 0

Abstract

Ongoing therapeutic advances in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) have significantly reduced the risk of death in AAV, but 30%-50% of patients still relapse. Relapse is a major problem in these diseases, leading to increased morbidity and mortality. It is, therefore, necessary to find predictors of relapse at the end of the remission induction and maintenance phases in order to personalize treatment.

查看原文本刊更多论文

抗中性粒细胞胞浆抗体（ANCA）相关性血管炎复发风险因素的最新进展。

抗中性粒细胞胞浆抗体相关性血管炎（AAV）的治疗不断取得进展，大大降低了AAV患者的死亡风险，但仍有30%-50%的患者会复发。复发是这些疾病的一个主要问题，会导致发病率和死亡率上升。因此，有必要找到缓解诱导和维持阶段结束时的复发预测因素，以便进行个性化治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental immunology 医学-免疫学

CiteScore

8.40

自引率

2.20%

发文量

101

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.